Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NBSE NASDAQ:OBSV NASDAQ:REVB NASDAQ:SNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/AOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs18 shsREVBRevelation Biosciences$2.95+3.9%$4.01$2.11▼$168.00$4.53M-0.08140,227 shs373,814 shsSNPXSynaptogenix$10.11+7.6%$4.76$1.84▼$7.85$14.05M1.08249,525 shs548,834 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%OBSVObsEva0.00%-75.00%-75.00%-75.00%-75.00%REVBRevelation Biosciences0.00%+5.73%+23.75%-68.07%-96.64%SNPXSynaptogenix+7.55%+12.46%+146.59%+378.01%+125.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AREVBRevelation Biosciences0.9527 of 5 stars0.05.00.00.00.80.01.3SNPXSynaptogenix0.0474 of 5 stars0.02.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNBSENeuBase Therapeutics 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ASNPXSynaptogenix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$27.05 per shareN/ASNPXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/AREVBRevelation Biosciences-$15.04M-$307.86N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)SNPXSynaptogenix-$12.77M-$10.08N/A∞N/AN/A-115.28%-58.31%N/ALatest SNPX, NBSE, OBSV, and REVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025N/AREVBRevelation Biosciences-$4.46N/AN/AN/AN/AN/A5/15/2025Q1 2025SNPXSynaptogenixN/A$0.04N/A$0.04N/AN/A5/8/2025Q1 2025REVBRevelation Biosciences-$20.64-$6.33+$14.31-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNBSENeuBase TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNBSENeuBase TherapeuticsN/AN/AN/AOBSVObsEvaN/A0.610.61REVBRevelation BiosciencesN/A3.603.60SNPXSynaptogenixN/A72.5972.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNBSENeuBase Therapeutics12.37%OBSVObsEva17.52%REVBRevelation Biosciences12.80%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipNBSENeuBase Therapeutics7.90%OBSVObsEva14.40%REVBRevelation Biosciences2.30%SNPXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableREVBRevelation Biosciences101.53 million1.50 millionNot OptionableSNPXSynaptogenix41.39 million1.35 millionNot OptionableSNPX, NBSE, OBSV, and REVB HeadlinesRecent News About These CompaniesTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024August 16, 2024 | investorplace.comSynaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord InjuryJuly 19, 2024 | markets.businessinsider.comSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryJuly 18, 2024 | prnewswire.comSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisJune 26, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024May 20, 2024 | investorplace.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryMay 7, 2024 | prnewswire.comSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | finanznachrichten.deMedia Sentiment Over TimeSNPX, NBSE, OBSV, and REVB Company DescriptionsNeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Revelation Biosciences NASDAQ:REVB$2.95 +0.11 (+3.87%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.95 0.00 (0.00%) As of 07/18/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.Synaptogenix NASDAQ:SNPX$10.11 +0.71 (+7.55%) As of 07/18/2025Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
